首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
【24h】

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation

机译:基于钙素抑制剂的甲氨蝶呤和霉酚酸酯的甲氨蝶呤和霉酚酸酯的比较分析预防抗移植物与宿主疾病后异烯类移植术后

获取原文
获取原文并翻译 | 示例
       

摘要

The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P .001) and grade Ill to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results. (C) 2018 American Society for Blood and Marrow Transplantation.
机译:钙碱抑制剂(CNI)如Tacrolimus(TAC)或环孢菌素(CYSP)与甲氨蝶呤(MTX)或霉酚酸酯MOFETIL(MMF)的组合通常用于降低后的移植物与宿主疾病(GVHD)预防─强度调节(RIC)同种异体造血细胞移植(ALLOHCT),但数据比较了2个方案的功效有限。我们评估了1564名接受Ric Allohct的成人患者,用于急性髓性白血病(AML)和急性淋巴细胞白血病(ALL),慢性髓性白血病(CML)和Myelodysplastic综合征(MDS)使用HLA相同的兄弟姐妹(匹配相关供体[MRD])或不相关的供体(URD)外周血移植和接受MTX或MMF的CYSP或TAC用于GVHD预防。该研究的主要结果是急性和慢性GVHD和总存活(OS)。该研究将患者人口分为4个基于方案:MMF-TAC,MMF-CYSP,MTX-TAC和MTX-CYSP的4个队列。在URD组中,MMF-CYSP与II级急性GVHD级的风险增加有关(相对风险[RR],1.78; p&。(1.78; p&。 006)与MTX-TAC相比。在URD组中,使用MMF-TAC(与MTX-TAC)导致更高的非卷复性死亡率。 (危险比,1.48; p = .008)。在任一组中,慢性GVHD,无病生存和GVHD预防方案中的OS没有差异。对于使用MRD的RIC AllOhct,基于GVHD预防的结果没有差异。然而,通过URD RiC AllOhct,MMF-Cysp差不多是基于MTX的急性GVHD预防方案,但在慢性GVHD和OS方面相当于所有方案。预期研究,瞄准URD接收者需要确认这些结果。 (c)2018年美国血液和骨髓移植学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号